Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
暂无分享,去创建一个
A. Levis | V. Pavone | G. Gaidano | A. Santoro | P. Zinzani | U. Ricardi | G. Ciccone | G. Rossi | E. Borsatti | U. Vitolo | L. Rigacci | E. Brusamolino | A. Pulsoni | F. Zaja | A. Castagnoli | G. Sacchetti | A. Broccoli | A. Anastasia | R. Freilone | C. Rusconi | C. Stelitano | A. Evangelista | P. Pregno | F. Salvi | M. Tani | L. Argnani | M. Bonfichi | D. Gioia
[1] O. Casasnovas,et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] V. Diehl,et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. , 2013, The Lancet. Oncology.
[3] J. Rowe,et al. A 10‐year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved , 2012, American journal of hematology.
[4] A. Rossi,et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.
[5] A. Rossi,et al. Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses , 2011, British journal of haematology.
[6] V. Diehl,et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Nihashi,et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Angrilli,et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[10] A. Santoro,et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients , 2007, Bone Marrow Transplantation.
[11] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Rowe,et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. , 2007, Blood.
[15] S. Pileri,et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] P. Gobbi,et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma , 2004, Cancer.
[17] P. Gobbi,et al. Comparison of prognostic models in patients with advanced Hodgkin disease , 2001, Cancer.
[18] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[19] M. Baccarani,et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[20] V. Diehl,et al. ABVD versus BEACOPP for Hodgkin's lymphoma. , 2011, The New England journal of medicine.
[21] A. Nagler,et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] A. Santoro,et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. , 2007, Haematologica.
[23] A. Levis,et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.
[24] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.